Endurx Pharmaceuticals
EnduRx is a virtual, pre-clinical company focused on developing peptide-directed nanoparticle drug delivery platforms and therapeutics for hard-to-treat solid tumors and other indications, aiming to improve drug efficacy, safety, and patient experience through tumor-specific delivery of active pharmaceutical ingredients.
Industries
Nr. of Employees
small (1-50)
Products
Nanoparticle candidate for triple-negative breast cancer (preclinical/IND-enabling)
Peptide-directed polymeric nanoparticle program targeting a mitochondrial protein translocated to the surface of tumor-associated cells; undergoing preclinical development with IND-enabling work planned.
Intraperitoneal nanoparticle program for ovarian cancer and peritoneal carcinomatosis
Nanoparticle delivery program optimized for intraperitoneal administration to concentrate therapeutic payloads within the peritoneal cavity for ovarian cancer indications.
Blood–brain barrier-penetrant nanoparticle program for brain tumors
Program to develop nanoparticles and targeting strategies intended to cross the blood–brain barrier and deliver therapeutic payloads to glioblastoma and other brain tumors.
Macrophage-targeted nanoparticle program for atherosclerotic plaque reduction
Therapeutic approach focused on delivering agents to macrophage components of atherosclerotic plaque as a non-lipid strategy to reduce plaque burden in preclinical models.
Nanoparticle candidate for triple-negative breast cancer (preclinical/IND-enabling)
Peptide-directed polymeric nanoparticle program targeting a mitochondrial protein translocated to the surface of tumor-associated cells; undergoing preclinical development with IND-enabling work planned.
Intraperitoneal nanoparticle program for ovarian cancer and peritoneal carcinomatosis
Nanoparticle delivery program optimized for intraperitoneal administration to concentrate therapeutic payloads within the peritoneal cavity for ovarian cancer indications.
Blood–brain barrier-penetrant nanoparticle program for brain tumors
Program to develop nanoparticles and targeting strategies intended to cross the blood–brain barrier and deliver therapeutic payloads to glioblastoma and other brain tumors.
Macrophage-targeted nanoparticle program for atherosclerotic plaque reduction
Therapeutic approach focused on delivering agents to macrophage components of atherosclerotic plaque as a non-lipid strategy to reduce plaque burden in preclinical models.
Services
Planning and executing preclinical studies required to support IND-enabling packages and first-in-human trial initiation for nanoparticle therapeutics.
Partnerships to apply peptide-directed nanoparticle delivery to approved drugs or development candidates to enhance tumor specificity and reduce systemic toxicity.
Planning and executing preclinical studies required to support IND-enabling packages and first-in-human trial initiation for nanoparticle therapeutics.
Partnerships to apply peptide-directed nanoparticle delivery to approved drugs or development candidates to enhance tumor specificity and reduce systemic toxicity.
Expertise Areas
- Nanoparticle drug delivery
- Peptide-targeted therapeutics
- Preclinical oncology development
- IND-enabling studies and regulatory planning
Key Technologies
- Peptide-functionalized polymeric nanoparticles
- Tumor-targeted payload encapsulation
- Intraperitoneal drug administration
- Blood–brain barrier penetration strategies